The Glutamate Hypothesis: A Pathogenic Pathway from which Pharmacological Interventions have Emerged

Abstract

We discuss the relevance of the glutamate hypothesis in explaining cognitive disturbances and negative symptoms in schizophrenia. 4 lines of evidence support the hypothesis that glutamate deregulation, mainly through dysfunction of the N-methyl-D-aspartate (NMDA) receptor, is an important underlying mechanism of schizophrenia. Glutamate pathways are promising sites for intervention. Glutamate agonists combined with non-clozapine antipsychotics and glutamate antagonists augmented to clozapine show interesting clinical benefits in refractory schizophrenia. We illustrate how unique properties of the NMDA receptor antagonist memantine in addition to clozapine, may cause improvement of positive, negative and cognitive symptoms of schizophrenia.

Key words

schizophrenia - glutamate - NMDA receptor - clozapine - glycine

• References

• 1 Buchanan RW, Davis M, Goff D et al. A Summary of the FDANIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia. Schizophr Bull 2005; 31: 5-19
• 2 Heaton RK, Gladsjo JA, Palmer BW et al. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 2001; 58: 24-32
• 3 Javitt DC. glutamate involvement in schizophrenia: focus on N-methyl-D-aspartate receptors. Prim Psychiatry 2006; 13: 38-46
• 4 Stone JM, Morrison PD, Pilowsky LS. Review: glutamate and dopamine dysregulation in schizophrenia – a synthesis and selective review. J Psychopharmacol 2007; 21: 440-452
• 5 Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ et al. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005; 20: 409-415
• 6 Schulte R. Clozapin bei therapieresistenter Schizophrenie. Plasmaspiegel und Dauer eines ausreichenden Behandlungs-versuchs. Psychopharmakotherapie 2003; 1-11
• 7 Loonen AJM, Stahl SM. Functional psychopharmacology is the way to go in pharmacotherapy for psychiatric disorders. Acta Psychiatr Scand 2010; 122: 435-437
• 8 Kornmeier J, Sosic-Vasic Z. Parallels between spacing effects during behavioural and cellular learning. Front Hum Neurosci 2012; 6: 203
• 9 Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367-1377
• 10 Papanastasiou E, Stone JM, Shergill S. When the drugs don’t work: the potential of glutamatergic antipsychotics in schizophrenia. Br J Psychiatry 2013; 202: 91-93
• 11 Harrison PJ, Lyon L, Sartorius LJ et al. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol 2008; 22: 308-322
• 12 Marino MJ, Conn PJ. Direct and indirect modulation of the N-methyl D-aspartate receptor. Curr Drug Targets CNS Neurol Disord 2002; 1: 1-16
• 13 Fell MJ, McKinzie DL, Monn JA et al. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology 2012; 62: 1473-1483
• 14 Allen P, Luigjes J, Howes OD et al. Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals. Schizophr Bull 2012; 38: 1268-1276
• 15 Moghaddam B, Adams B, Verma A et al. Activation of glutmatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921-2927
• 16 Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2006; Issue 2. Art. No.: CD003730
• 17 Takata A, Iwayama Y, Fukuo Y et al. A population-specific uncommon variant in GRIN3A associated with schizophrenia. Biol Psychiatry 2013; 73: 532-539
• 18 Wandinger KP, Saschenbrecker S, Soecker W et al. Anti-NMDA-receptor encephalitis: A severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol 2011; 231: 86-91
• 19 Steiner J, Walter M, Glanz W et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013; 70: 271-278
• 20 Marsman A, van den Heuvel MP, Klomp DW et al. Glutamate in Schizophrenia: A focused review and meta-analysis of ¹H-MRS studies. Schizophr Bull 2011; 1-10
• 21 Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007; 27: 11496-11500
• 22 Gordon JA. Testing the glutamate hypothesis of schizophrenia. Nat Neurosci 2010; 13: 2-4
• 23 Jackson M, Homayoun H, Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sic USA 2004; 101: 6391-6396
• 24 Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS drugs 2011; 25: 859-885
• 25 Goff DC, Leahy L, Berman I et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001; 21: 484-487
• 26 Conn PJ, Lindsley CW, Jones CK. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends in Pharmacol Sci 2009; 30: 25-31
• 27 Fraley ME. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat 2009; 19: 1259-1275
• 28 Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 2007; 13: 1102-1107
• 29 Kinon BJ, Zhang L, Millen BA et al. HBBI Study Group . A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 2011; 31: 349-355
• 30 Kinon B, Millen BA, Downing AC et al. LY, 2140023 monohydrate in the treatment of patients with schizophrenia: results of 2 clinical trials assessing efficacy in treating acutely ill and those with prominent negative symptoms. Schizophr Bull 2013; 39: S338
• 31 Adams DH, Kinon BJ, Baygani S et al. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC Psychiatry 2013; 13: 143
• 32 Adams DH, Zhang L, Millen BA et al. Pomaglumetad methionil (LY2140023 monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison. Schizophr Res Treatment 2014; 1-11
• 33 Trabanco AA, Cid JM. mGluR2 positive allosteric modulators: a patent review (2009-present). Expert Opin Ther Pat 2013; 23: 629-647
• 34 Hopkins CR. Is there a path forward for mGlu(2) positive allosteric modulators for the treatment of schizophrenia?. ACS Chem Neurosci 2013; 20: 211-213
• 35 Javitt DC. Twenty-five years of glutamate in schizophrenia: are we there yet?. Schizophr Bull 2012; 38: 911-913
• 36 Emmett MR, Mick SJ, Cler JA et al. Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology 1991; 30: 1167-1171
• 37 Lane HY, Huang CL, Wu PL et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006; 60: 645-649
• 38 Kane J, Honigfeld G, Singer J et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796
• 39 Naheed M, Geen B. Focus on clozapine. Curr Med Res Opin 2001; 17: 223-229
• 40 Howes OD, Egerton A, Allan V et al. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights form PET and SPECT imaging. Current Pharmaceutical Design 2009; 15: 2550-2559
• 41 Yeun EY, Zhong P, Yan Z. Homeostatic regulation of glutamatergic transmission by dopamine D4 receptors. Proc Natl Acad Sci USA 2010; 107: 22308-22313
• 42 Tanahashi S, Yamamura S, Nakagawa M et al. Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol 2012; 165: 1543-1555
• 43 Veerman SRT, Schulte PFJ, Begemann MJH et al. Clozapine Augmented with Glutamate Modulators in Refractory Schizophrenia: A Review and Meta-analysis. Pharmacopsychiatry 2014; in press
• 44 Joshi I, Yang Y-M, Wang L-Y. Cellular/molecular coincident activation of metabotropic glutamate receptors and NMDA receptors (NMDARs) downregulates perisynaptic/extrasynaptic NMDARs and enhances high-fidelity neurotransmission at the developing calyx of the held synapse. J Neurosci 2007; 27: 9989-9999
• 45 Tiihonen J, Hallikainen T, Ryynänen OP et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 2003; 54: 1241-1248
• 46 Tiihonen J, Halonen P, Wahlbeck K et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 2005; 66: 1012-1015
• 47 Behdani F, Hebrani P, Rezaei Ardani A et al. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial. Arch Iran Med 2011; 14: 270-275
• 48 Tsouli S, Konitsiotis S. How should we treat a patient with early Parkinson’s disease?. Int J Clin Pract 2010; 64: 1210-1219
• 49 Ossola B, Schendzielorz N, Chen SH et al. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia. Neuropharmacology 2011; 61: 574-582
• 50 de Lucena D, Fernandes BS, Berk M et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009; 70: 1416-1423
• 51 Kremer I, Vass A, Gorelik I et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 2004; 56: 441-446
• 52 Kishi T, Iwata N. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. J Psychiatr Res 2013; 1-7
• 53 Angus S, Sugars J, Boltezar R et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1997; 17: 88-91
• 54 Silver H, Goodman C, Isakov V et al. A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. Int Clin Psychopharmacol 2005; 20: 319-326
• 55 Pappa S, Tsouli S, Apostolou G et al. Effects if amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 2010; 33: 271-275
• 56 Rezaei F, Mohammad-karimi M, Seddighi S et al. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2013; 33: 1-7
• 57 Lieberman JA, Papadakis K, Csernansky J et al. MEM-MD-29 Study Group . A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 2009; 34: 1322-1329
• 58 Lee JG, Lee SW, Lee BJ et al. Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry Investig 2012; 9: 166-173
• 59 Os van J, Kahn R. Remissiecriteria voor de diagnose schizofrenie. Tijdschr Psychiatr 2007; 49: 21-26
• 60 Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev 2005; CD003154
• 61 Winblad B, Jones RW, Wirth Y et al. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007; 24: 20-27
• 62 Levaux MN, Potvin S, Sepehry AA et al. Computerized assessment of cognition in schizophrenia: Promises and pitfalls of CANTAB. Eur Psychiatry 2007; 22: 104-115
• 63 Guy W. Clinical Global Impression Scale. In Guy W. ECDEU Assessment Manual for Psychopharmacology- Revised. Rockville MD: US Dept. of Health, Education and Welfare, ADAMHA, MIMH Psychopharmacology Research Branch; 1976. 218-222
• 64 Kay SR, Flszbein A, Opfer LA. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull 1987; 13: 261-276
• 65 Baron-Cohen S, Wheelwright S, Hill J et al. The “Reading the Mind in the Eyes” Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry 2001; 42: 241-251
• 66 Wing J, Lelliott P, Chaplin RH. Reliability and validity of HoNOS (multiple letters). Psychiatric Bull 1999; 23: 375
• 67 Priebe S, Huxley P, Knight S et al. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry 1999; 45: 7-12
• 68 Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1362-1374
• 69 Muhonen LH, Lönnqvist J, Juva K et al. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 2008; 69: 392-399
• 70 Stewart SE, Jenike EA, Hezel DM et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol 2010; 30: 34-39
• 71 Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990; 3: 247-251
• 72 Goodman WK, Price LH, Rasmussen SA et al. The Yale-Brown Obsessive Compulsive Scale. Arch Gen Psychiatry 1989; 46: 1012-1016
• 73 Day JC, Wood G, Dewey M et al. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 1995; 166: 650-653